MX2017014140A - Proteinas agonistas receptoras cd40 de cadena simple. - Google Patents

Proteinas agonistas receptoras cd40 de cadena simple.

Info

Publication number
MX2017014140A
MX2017014140A MX2017014140A MX2017014140A MX2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A
Authority
MX
Mexico
Prior art keywords
receptor agonist
agonist proteins
chain
proteins
cd40l
Prior art date
Application number
MX2017014140A
Other languages
English (en)
Inventor
Hill Oliver
Gieffers Christian
Thiemann Meinolf
Schnyder Tim
Original Assignee
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag filed Critical Apogenix Ag
Publication of MX2017014140A publication Critical patent/MX2017014140A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

Se proporcionan en la presente proteínas agonistas receptoras CD40, ácidos nucleicos que codifican para las mismas, y métodos para tratar a un sujeto que presenta una enfermedad o trastorno asociado con CD40L. Las proteínas agonistas receptoras CD40 proporcionadas en la presente comprenden tres dominios solubles CD40L y un fragmento Fc. Las proteínas agonistas receptoras CD40 son sustancialmente no agregantes y adecuadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.
MX2017014140A 2015-05-04 2016-05-04 Proteinas agonistas receptoras cd40 de cadena simple. MX2017014140A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156813P 2015-05-04 2015-05-04
PCT/EP2016/059983 WO2016177771A1 (en) 2015-05-04 2016-05-04 Single-chain cd40-receptor agonist proteins

Publications (1)

Publication Number Publication Date
MX2017014140A true MX2017014140A (es) 2018-03-15

Family

ID=56087236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014140A MX2017014140A (es) 2015-05-04 2016-05-04 Proteinas agonistas receptoras cd40 de cadena simple.

Country Status (12)

Country Link
US (2) US10793616B2 (es)
EP (1) EP3292143B1 (es)
JP (1) JP6738831B2 (es)
KR (1) KR20170138585A (es)
CN (1) CN107709355B (es)
AU (1) AU2016257000B2 (es)
BR (1) BR112017023646A2 (es)
CA (1) CA2984350A1 (es)
ES (1) ES2754432T3 (es)
MX (1) MX2017014140A (es)
RU (1) RU2745801C2 (es)
WO (1) WO2016177771A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44993A (fr) * 2016-05-13 2019-03-20 Medimmune Llc Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
AU2017371217B2 (en) 2016-12-09 2020-03-19 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
EP3781203A4 (en) 2018-04-20 2022-04-13 Lyvgen Biopharma Co., Ltd. ANTI-CD40 ANTIBODIES AND USES THEREOF
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
LT4186920T (lt) 2018-06-29 2024-04-25 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
WO2020065409A2 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
EP3856790A4 (en) 2018-09-28 2022-09-28 Lyvgen Biopharma Holdings Limited ANTI-CD40 BINDING MOLECULES WITH MODIFIED CF DOMAINS AND THEIR THERAPEUTIC USES
EP3947454A1 (en) * 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
US20220324988A1 (en) 2019-04-10 2022-10-13 Nankai University Anti-CD40 antibodies and uses thereof
CN110760541B (zh) * 2019-10-31 2022-03-29 中国农业科学院兰州兽医研究所 用中国仓鼠卵巢细胞表达外源蛋白时信号肽的选择方法及应用
IL294051A (en) 2019-12-19 2022-08-01 Akston Biosciences Corp Long-acting insulin-fc fusion proteins, and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HRP20230990T1 (hr) 2020-04-10 2023-12-08 Akston Biosciences Corporation Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
AU2004224123A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2009060159A1 (en) * 2007-11-08 2009-05-14 Medigene Limited Mutated ilt molecules
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
EP2825191B1 (en) * 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
US10071169B2 (en) * 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
NO2776305T3 (es) * 2014-04-23 2018-01-27

Also Published As

Publication number Publication date
KR20170138585A (ko) 2017-12-15
US20180066036A1 (en) 2018-03-08
CN107709355A (zh) 2018-02-16
EP3292143A1 (en) 2018-03-14
EP3292143B1 (en) 2019-08-21
US20210032309A1 (en) 2021-02-04
BR112017023646A2 (pt) 2018-07-17
RU2745801C2 (ru) 2021-04-01
RU2017141727A (ru) 2019-06-04
JP2018515072A (ja) 2018-06-14
CN107709355B (zh) 2021-09-14
WO2016177771A1 (en) 2016-11-10
CA2984350A1 (en) 2016-11-10
ES2754432T3 (es) 2020-04-17
US10793616B2 (en) 2020-10-06
JP6738831B2 (ja) 2020-08-12
AU2016257000A1 (en) 2017-11-23
RU2017141727A3 (es) 2019-11-05
AU2016257000B2 (en) 2020-05-14
WO2016177771A9 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
MX2019006954A (es) Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
MX2017016253A (es) Anticuerpos para cd40.
MX2016014647A (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
MX2017001138A (es) Metodo.
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP3437683A4 (en) TEMPERATURE RETENTION AND CONTRAST AGENT INJECTION SYSTEM FOR A MICROCATHTER, AND SYSTEM FOR TEMPERATURE RETENTION AND INJECTION OF A THERAPEUTIC SUSPENSION MEDICINAL SUBSTANCE
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
NZ761611A (en) Single-chain trail-receptor agonist proteins
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей